Dr John Stageman awarded an OBE in the 2012 New Years honours list.
4 January 2012
John received the honour for services to the UK Biotechnology Industry. He is currently Chairman of Bionow Ltd, a member of the Biotechnology and Biological Sciences Research Council, a Board member of NWDA, Chairman of the HealthTech and Medicines Knowledge Transfer Network for the Technology Strategy Board (TSB) and an Honorary Professor in Life Sciences at the University of Manchester.
Upon receiving the news John commented "I’m absolutely thrilled to be recognised by this special award in the New Years Honours. The last 30 years has seen a seismic revolution in molecular biology and I have had the immense privilege of being at the "R&D" heart of its industrial application. Applying innovative science successfully is all about teamwork so I must say sincere thanks to my many colleagues, collaborators and managers who have made my exciting career possible and helped to make real ‘impacts’ happen. I hope I can use the next few years to exploit my experiences with smaller companies and public/private partnerships, to do it faster and better than we did!"
Dr Stageman started his career in ICI at Billingham working on large scale industrial biotechnology projects including Single Cell Protein and Biodegradable polymers from bacterial fermentation. He led the team that scaled up to the first large scale manufacturing process for Quorn. Moving into the Pharmaceutical business that became AstraZeneca, John was a constant champion of biotechnology and genomics leading new investments pharmacogenetics and recombinant protein development and pilot production. He was responsible for developing AstraZeneca’s competitive biopharmaceutical strategy, leading to the acquisition of Cambridge Antibody Technology and of MedImmune. After a period in a transitional role as General Manager of MedImmune Cambridge, John returned to the North West as Vice President of UK Science Affairs, retiring from Astra Zeneca in 2011.
Sponsors
Partners
